Strongyloidiasis Antibodies Found in Transplant Donors
|
By LabMedica International staff writers Posted on 10 Dec 2018 |

Image: A histopathology of Strongyloides stercoralis in the duodenum (Photo courtesy of Dr. Raul S. Gonzalez, MD).
Strongyloidiasis is a neglected tropical disease caused by a parasite, which is endemic in most parts of the world. It can cause a life-threatening disease among immunosuppressed individuals and can be transmitted from solid organ transplant (SOT) donors to recipients.
Due to the characteristic life cycle of Strongyloides stercoralis, individuals can carry the infection lifelong with mild or no symptoms, unless treated. The disease endemic in large parts of Latin America, Asia and Africa with an estimated prevalence of more than 400 million infected.
Scientists at the Universitat de Barcelona (Barcelona, Spain) carried out a retrospective study including all deceased individuals from endemic areas for strongyloidiasis who were considered for organ donation between January 2004 and December 2014 in the Hospital Clinic. During the period 2004–2014, 1,025 deceased individuals were evaluated as potential deceased organ donors. Of these, 90 donors (8.78%) were native from endemic areas for strongyloidiasis. Most were males (63/90 cases; 70%) and median age of all cases was 41 years old. More than half of the deceased organ donors from endemic areas had been born in Latin America (49/90 cases; 54.44%), whereas the rest were from Southeast Asia (24/90 cases; 26.67%) and Africa (17/90 cases; 18.89%).
The team used the serum samples of potential donors from endemic areas for strongyloidiasis, and performed a S. stercoralis serological test. The commercial test IVD-ELISA, which detects immunoglobulin G (IgG) antibodies by using somatic antigens from larvae of the parasite, was used and has a sensitivity of 91.2%, and a specificity of 99.1%. Currently, IVD-ELISA is the available test in the hospital. The sample is defined as positive if the absorbance/0.2 (i) > 1.1.
The scientists found there were only in 65 of 90 cases available serum samples and analyzed for S. stercoralis serology and 6/65 cases (9.23%) were found to have a positive test for strongyloidiasis. S. stercoralis serology indices ranged between 1.84 and 9.32. From the six positive cases, three individuals were native from Latin America (two from Brazil and one from Ecuador), two from Africa (Senegal and Ghana) and one from Southeast Asia (Philippines).
The authors concluded that they had found a high seroprevalence of strongyloidiasis in individuals from endemic settings evaluated as potential deceased donors for SOT. The data reinforce the importance of following current guidelines recommending systematic screening of potential donors from endemic areas. There is an urgent need to develop rapid diagnostic tests, which can be used in daily clinical practice. The study was published on November 29, 2018, in the journal Public Library of Science Neglected tropical Diseases.
Related Links:
Universitat de Barcelona
Due to the characteristic life cycle of Strongyloides stercoralis, individuals can carry the infection lifelong with mild or no symptoms, unless treated. The disease endemic in large parts of Latin America, Asia and Africa with an estimated prevalence of more than 400 million infected.
Scientists at the Universitat de Barcelona (Barcelona, Spain) carried out a retrospective study including all deceased individuals from endemic areas for strongyloidiasis who were considered for organ donation between January 2004 and December 2014 in the Hospital Clinic. During the period 2004–2014, 1,025 deceased individuals were evaluated as potential deceased organ donors. Of these, 90 donors (8.78%) were native from endemic areas for strongyloidiasis. Most were males (63/90 cases; 70%) and median age of all cases was 41 years old. More than half of the deceased organ donors from endemic areas had been born in Latin America (49/90 cases; 54.44%), whereas the rest were from Southeast Asia (24/90 cases; 26.67%) and Africa (17/90 cases; 18.89%).
The team used the serum samples of potential donors from endemic areas for strongyloidiasis, and performed a S. stercoralis serological test. The commercial test IVD-ELISA, which detects immunoglobulin G (IgG) antibodies by using somatic antigens from larvae of the parasite, was used and has a sensitivity of 91.2%, and a specificity of 99.1%. Currently, IVD-ELISA is the available test in the hospital. The sample is defined as positive if the absorbance/0.2 (i) > 1.1.
The scientists found there were only in 65 of 90 cases available serum samples and analyzed for S. stercoralis serology and 6/65 cases (9.23%) were found to have a positive test for strongyloidiasis. S. stercoralis serology indices ranged between 1.84 and 9.32. From the six positive cases, three individuals were native from Latin America (two from Brazil and one from Ecuador), two from Africa (Senegal and Ghana) and one from Southeast Asia (Philippines).
The authors concluded that they had found a high seroprevalence of strongyloidiasis in individuals from endemic settings evaluated as potential deceased donors for SOT. The data reinforce the importance of following current guidelines recommending systematic screening of potential donors from endemic areas. There is an urgent need to develop rapid diagnostic tests, which can be used in daily clinical practice. The study was published on November 29, 2018, in the journal Public Library of Science Neglected tropical Diseases.
Related Links:
Universitat de Barcelona
Latest Immunology News
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







